A Phase Ib Multicenter Dose-Finding and Safety Study of Venetoclax and Obinutuzumab in Patients With Relapsed or Refractory or Previously Untreated Chronic Lymphocytic Leukemia
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 01 Jun 2017
At a glance
- Drugs Obinutuzumab (Primary) ; Venetoclax (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions
- Sponsors Genentech
- 24 May 2017 Planned End Date changed from 1 May 2019 to 2 Apr 2019.
- 24 May 2017 Planned primary completion date changed from 1 May 2019 to 2 Apr 2019.
- 01 Aug 2016 Status changed from recruiting to active, no longer recruiting.